Crescent Biopharma (NASDAQ:CBIO) Upgraded by Wall Street Zen to Sell Rating

Crescent Biopharma (NASDAQ:CBIO) was upgraded by equities researchers at Wall Street Zen to a “sell” rating in a report released on Saturday.

Other analysts have also recently issued reports about the stock. Lifesci Capital raised shares of Crescent Biopharma to a “strong-buy” rating and set a $22.00 target price on the stock in a report on Wednesday, June 18th. Stifel Nicolaus initiated coverage on shares of Crescent Biopharma in a report on Wednesday, June 25th. They set a “buy” rating and a $28.00 target price on the stock. Finally, TD Cowen raised shares of Crescent Biopharma to a “strong-buy” rating in a report on Friday, June 20th.

Crescent Biopharma Stock Performance

Shares of NASDAQ:CBIO opened at $12.96 on Friday. The firm has a market cap of $253.37 million, a price-to-earnings ratio of -0.28 and a beta of 1.52. Crescent Biopharma has a 1-year low of $11.06 and a 1-year high of $63.00.

Crescent Biopharma Company Profile

Crescent Biopharma, Inc operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.